Tolera Therapeutics, Inc.

Tolera Therapeutics, Inc.

Tolera Therapeutics, Inc.

Overview
Date Founded

2007

Headquarters

315 East Eisenhower Parkway,Suite 100,Ann Arbor, MI 48108

Type of Company

Private

Employees (Worldwide)

11 - 50

Industries

Other Business & Consulting Services
Pharmaceuticals
Holding Companies
Medical Support Services
Biotechnology

Company Description

Tolera Therapeutics, Inc. develops novel therapies and technologies for immune modulation. Its products include anti-aßTCR antibody an immune induction therapy in solid organ transplantation and graft versus host disease. The company was founded by Jake Orville, Maria Siemionow, James J. Herrmann and John J. Puisis in 2007 and is headquartered in Ann Arbor, MI.

Executives & Employees

Head-Analytics & Quality

Board of Directors

Co-Founder at Triathlon Medical Venture Partners LLC

General Partner at APJohn Ventures Annex Fund LP

Fund Advisor at Hopen LS Manager II LLC

Fund Advisor at Hopen LS Manager II LLC

Paths to Tolera Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Tolera Therapeutics, Inc.
Recent Transactions
Details Hidden

Tolera Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Tolera Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Tolera Therapeutics, Inc. raised money in a private placement transaction

Investors
Details Hidden

Open Prairie Ventures invests in high growth information technology, wireless communication and life science technology companies. They look for companies with efficient capital usage and disruptive technologies. Areas near major universities noted for research and innovation are an essential part of their focus. They seek to utilize less than $5 million of capital to generate meaningful revenue and to deploy less than $15 million of syndicated capital to develop, commercialize and exit their investments. Open Prairie Ventures prefers to be the lead investor, or co-lead investor in pre-revenue portfolio companies, and to syndicate with their venture network as post-revenue growth requires additional capital.

Details Hidden

Triathlon Medical Venture Partners invests exclusively in the life sciences sector. They provide equity capital to early and expansion stage companies with proprietary biomedical technology platforms or products addressing significant human healthcare needs. The firm focuses on early-stage opportunities in the Midwestern US, but they also consider mid- to later-stage companies throughout the US. Triathlon will lead as well as co-invest. Initial investments range from $500,000 to $3 million and up to $7 million over subsequent rounds.

Details Hidden

Hopen Life Sciences focuses on investments in a portfolio of early- to mid-stage life science companies in the areas of diagnostics, therapeutics, pharmaceuticals, medical devices, and enabling technologies. They seek to identify healthcare companies with innovations that meet an unmet market need s and to assist companies in accelerating their products' time to market. The firm is not bound by specific disease indications, market size or geographic region. Investments have ranged from $150,000 to $5 million, although Hopen Therapeutics Group prefers to make investments in the range of $200,000 to $2 million. Hopen Life Sciences makes seed investments (with proof-of-concept) through Series B investments. They prefer to lead investment rounds or syndicates.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Tolera Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Tolera Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Tolera Therapeutics, Inc..